IL280377A - Gene signatures to predict melanoma metastases and disease progression in the patient - Google Patents
Gene signatures to predict melanoma metastases and disease progression in the patientInfo
- Publication number
- IL280377A IL280377A IL280377A IL28037721A IL280377A IL 280377 A IL280377 A IL 280377A IL 280377 A IL280377 A IL 280377A IL 28037721 A IL28037721 A IL 28037721A IL 280377 A IL280377 A IL 280377A
- Authority
- IL
- Israel
- Prior art keywords
- melanoma
- gene signatures
- patient prognosis
- predicting metastasis
- metastasis
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title 1
- 230000004547 gene signature Effects 0.000 title 1
- 201000001441 melanoma Diseases 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862703221P | 2018-07-25 | 2018-07-25 | |
| US201862750294P | 2018-10-25 | 2018-10-25 | |
| US201862778777P | 2018-12-12 | 2018-12-12 | |
| PCT/NL2019/050487 WO2020022895A2 (en) | 2018-07-25 | 2019-07-25 | Gene signatures for predicting metastasis of melanoma and patient prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL280377A true IL280377A (en) | 2021-03-25 |
Family
ID=68242821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280377A IL280377A (en) | 2018-07-25 | 2021-01-24 | Gene signatures to predict melanoma metastases and disease progression in the patient |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12473599B2 (enExample) |
| EP (1) | EP3827101B1 (enExample) |
| JP (1) | JP7633159B2 (enExample) |
| KR (1) | KR20210044233A (enExample) |
| CN (1) | CN113039289B (enExample) |
| AU (1) | AU2019310636B2 (enExample) |
| CA (1) | CA3107401A1 (enExample) |
| DK (1) | DK3827101T3 (enExample) |
| ES (1) | ES2966015T3 (enExample) |
| IL (1) | IL280377A (enExample) |
| WO (1) | WO2020022895A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102751357B1 (ko) * | 2021-07-16 | 2025-01-06 | 한림대학교 산학협력단 | 구강암의 임프절 전이 예측과 관련된 유전자군 |
| CA3240376A1 (en) * | 2021-12-08 | 2023-06-15 | Alexander MEVES | Assessing and treating melanoma |
| EP4445137A4 (en) * | 2021-12-08 | 2025-12-10 | Mayo Found Medical Education & Res | MELANOMA ASSESSMENT AND TREATMENT |
| WO2024108191A1 (en) * | 2022-11-18 | 2024-05-23 | University Of Virginia Patent Foundation | Machine learning approach to predicting lymph node metastases |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040010045A1 (en) | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| CA2505416A1 (en) | 2002-11-21 | 2004-06-10 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| US20070154889A1 (en) | 2004-06-25 | 2007-07-05 | Veridex, Llc | Methods and reagents for the detection of melanoma |
| US20060136145A1 (en) | 2004-12-20 | 2006-06-22 | Kuo-Jang Kao | Universal reference standard for normalization of microarray gene expression profiling data |
| TW200719903A (en) | 2005-04-19 | 2007-06-01 | Combinatorx Inc | Compositions for the treatment of neoplasms |
| NZ593226A (en) | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (efnb2) for colorectal cancer prognosis |
| US8450057B2 (en) | 2006-08-14 | 2013-05-28 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| PT2062049E (pt) | 2006-09-06 | 2014-07-28 | Univ California | Diagnóstico molecular e classificação de melanoma maligno |
| EP2152911A4 (en) | 2007-05-04 | 2010-05-19 | Dermtech Int | DIAGNOSIS OF MELANOMA BY NUCLEIC ACID ANALYSIS |
| EP2228457A1 (en) | 2007-08-16 | 2010-09-15 | Genomic Health, Inc. | Gene expression markers of recurrence risk in cancer patients after chemotherapy |
| CA2716357A1 (en) | 2008-03-05 | 2009-09-11 | The Regents Of The University Of California | Molecular diagnosis and classification of malignant melanoma |
| RU2011142806A (ru) | 2009-05-01 | 2013-06-10 | ОНКОЗИМ ФАРМА ИНК. (Канада) | Комбинации пентамидина для лечения рака |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| EP2619321B1 (en) | 2010-09-20 | 2018-08-01 | Advanced Cell Diagnostics, Inc. | Biomarkers for differentiating melanoma from benign nevus in the skin |
| EP3195869B1 (en) | 2012-07-27 | 2021-09-29 | Agency for Science, Technology and Research (A*STAR) | Method of promoting wound healing |
| WO2014077915A1 (en) | 2012-11-14 | 2014-05-22 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying malignant skin lesions |
| US20170275700A1 (en) | 2014-08-14 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer |
| KR20250004095A (ko) * | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| AU2017261688B2 (en) | 2016-05-10 | 2022-09-29 | Mayo Foundation For Medical Education And Research | Methods and materials for staging and treating skin cancer |
-
2019
- 2019-07-25 CN CN201980062825.7A patent/CN113039289B/zh active Active
- 2019-07-25 ES ES19787488T patent/ES2966015T3/es active Active
- 2019-07-25 JP JP2021528324A patent/JP7633159B2/ja active Active
- 2019-07-25 WO PCT/NL2019/050487 patent/WO2020022895A2/en not_active Ceased
- 2019-07-25 EP EP19787488.6A patent/EP3827101B1/en active Active
- 2019-07-25 CA CA3107401A patent/CA3107401A1/en active Pending
- 2019-07-25 AU AU2019310636A patent/AU2019310636B2/en active Active
- 2019-07-25 US US17/262,175 patent/US12473599B2/en active Active
- 2019-07-25 DK DK19787488.6T patent/DK3827101T3/da active
- 2019-07-25 KR KR1020217005548A patent/KR20210044233A/ko active Pending
-
2021
- 2021-01-24 IL IL280377A patent/IL280377A/en unknown
-
2025
- 2025-09-11 US US19/326,514 patent/US20260071281A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260071281A1 (en) | 2026-03-12 |
| JP2021531831A (ja) | 2021-11-25 |
| AU2019310636B2 (en) | 2025-06-26 |
| DK3827101T3 (da) | 2023-12-11 |
| US12473599B2 (en) | 2025-11-18 |
| EP3827101A2 (en) | 2021-06-02 |
| CN113039289A (zh) | 2021-06-25 |
| CA3107401A1 (en) | 2020-01-30 |
| ES2966015T3 (es) | 2024-04-17 |
| AU2019310636A1 (en) | 2021-02-04 |
| NZ771988A (en) | 2025-02-28 |
| US20210301353A1 (en) | 2021-09-30 |
| WO2020022895A3 (en) | 2020-04-02 |
| JP7633159B2 (ja) | 2025-02-19 |
| EP3827101B1 (en) | 2023-11-08 |
| WO2020022895A2 (en) | 2020-01-30 |
| KR20210044233A (ko) | 2021-04-22 |
| CN113039289B (zh) | 2025-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280377A (en) | Gene signatures to predict melanoma metastases and disease progression in the patient | |
| IL284400A (en) | Polypeptides useful for gene editing and methods of use | |
| ZA201608881B (en) | Floating structure and method of installing same | |
| EP3509947A4 (en) | METHODS AND SYSTEMS FOR LIFTING AND LOWERING A PAYLOAD | |
| GB202009760D0 (en) | Data de-identification based on detection of allowable configurations for data de-indentification processes | |
| IL276575A (en) | BTK inhibitors and their mutants | |
| EP3127040A4 (en) | Digital rock physics-based trend determination and usage for upscaling | |
| EP4245840A4 (en) | PROBIOTIC SYSTEM AND ITS USE | |
| IL276167A (en) | A biomarker for predicting treatment with infiltrating lymphocytes and its uses | |
| GB201806064D0 (en) | Improved Classification And Prognosis Of Prostate Cancer | |
| IL291378A (en) | Methods for filtering condensed matter related to specificity and their uses | |
| EP3665981C0 (en) | PROVISION AND USE OF INTERVALS FOR REFERENCE SIGNAL TIME DIFFERENCE MEASUREMENTS | |
| GB2591194B (en) | Modulation of gene expression and screening for deregulated protein expression | |
| EP3798316A3 (en) | Genes and gene signatures for diagnosis and treatment of melanoma | |
| IL281606A (en) | Radiomic signature of fat | |
| IL288970A (en) | Methods for detecting and predicting breast cancer | |
| EP3774730A4 (en) | CANCER METASTASIS INHIBITORS BY INHIBITING THE MIGRATION AND INVASION OF CANCER CELLS | |
| SG11202104101TA (en) | Method of detecting cancer and/or tuberculosis | |
| ZA202006927B (en) | Systems and methods for predicting aspects of an unknown event | |
| EP4265740A3 (en) | Methods for predicting risk of metastasis in cutaneous melanoma | |
| GB201812561D0 (en) | Biomarkers and uses thereof | |
| IL288045A (en) | Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases | |
| EP4372655C0 (en) | PERSONAL AND SECURE DIGITAL ELECTRONIC ACCESS PERMISSION | |
| GB201619808D0 (en) | Biomarkers for the prognosis and diagnosis of cancer | |
| EP4006151A4 (en) | BIOMARKER FOR ESOPHAGUS CANCER, AND ASSOCIATED APPLICATION |